SAN FRANCISCO — Left atrial appendage occlusion (LAAO) at the time of transcatheter aortic valve replacement (TAVR) using the WATCHMAN 2.5 device (Boston Scientific) is feasible and non-inferior to ...
Please provide your email address to receive an email when new articles are posted on . Temporarily stopping anticoagulant use during TAVR was safe among patients undergoing the procedure. An ...
LONDON -- It was best that people interrupt their oral anticoagulation (OAC) therapy around the time they get transcatheter aortic valve replacement (TAVR, also TAVI), the POPular PAUSE TAVI trial ...
SAN FRANCISCO -- Left atrial appendage occlusion (LAAO) at the time of transcatheter aortic valve replacement (TAVR) appeared as safe as TAVR alone, the WATCH-TAVR trial showed. For patients with ...
Please provide your email address to receive an email when new articles are posted on . Atrial fibrillation is associated with increased risk for bleeding and stroke in patients undergoing TAVR. Left ...
TCT 770: Clinical Outcomes of Combined RAAS Inhibitor and Statin Therapy in Patients Undergoing Transcatheter Aortic Valve Replacement: A Large-Scale Propensity-Matched Analysis Receive the the latest ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...
Predictors of a Positive Treadmill Stress Test in Patients with Asymptomatic Severe Aortic Stenosis: Insights from the EARLY TAVR Treadmill Registry Receive the the latest news, research, and ...
Patients who received a single antiplatelet drug therapy— usually aspirin — after transcatheter aortic valve replacement (TAVR) had about half the risk of dying in the subsequent 6 months compared ...
At the 2026 Society of Thoracic Surgeons (STS) Annual Meeting, investigators presented a late-breaking study focused on surgical aortic valve replacement (SAVR) following prior transcatheter aortic ...
Two observational studies indicate GLP-1 receptor agonists may reduce complications after transcatheter aortic valve replacement (TAVR) and carotid artery stenting (CAS). Post-TAVR tirzepatide use was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results